Source:Instrument Family,Reproduction without authorization is prohibited, and reproduction is allowed 24 hours later.

It is worth mentioning that Medtronic has had several recalls in recent years. At the same time, the regulatory oversight of medical devices worldwide has become increasingly strict. Some believe that appointing a new Chief Regulatory Officer will help promote the safe rollout of Medtronic's products globally.

Regarding the new personnel appointment, Yarmela Pavlovic posted on LinkedIn: "I am pleased to announce that,I was recently appointed as the Chief Regulatory Officer of Medtronic.Medtronic’s products reach the lives of 74 million patients every year, and I am honored to continue supporting our global mission.”

According to the LinkedIn profile,Pavlovic joined Medtronic in July 2021 as Vice President of Regulatory Strategy. She held this position until April 2023, when she became Vice President of Global Regulatory Affairs, Strategy, and Policy.In addition, after Pavlovic began her legal career at Pepper Hamilton LLP in 2003, she became a partner at Manatt, Phelps & Phillips and Hogan Lovells.

Yarmela Pavlovic

As the Chief Regulatory Officer of Medtronic,Pavlovic willLeadership SupervisionAffairs, and collaborate with Medtronic's operations department, regulatory heads from global regions, and Greater China to guide the overall direction of the company’s regulatory affairs. She and her team alsoWill guide the development of regulatory strategies for products such as artificial intelligence technology and connected devices.In addition, Pavlovic alsoWill lead the company's external global regulatory policy development efforts.

Pavlovic added: "Our impressive global regulatory expertise team,It is crucial for ensuring that our products obtain and maintain market approval worldwide."I am fortunate to work with such a talented group of people who work tirelessly to ensure we meet the important expectations of regulators, make meaningful contributions to the future of global regulation, and, most importantly, ensure that patients can access innovative and life-saving technologies in a timely manner, as they are at the heart of everything we do."

Medtronic spokesperson Sara Thatcher said in an email: "Yarmela, as our Chief Regulatory Officer,Can focus more on Medtronic's regulatory affairs, further ensuring that millions of patients have access to safe and effective medical devices.”

This seems to be since 2009,Medtronic has, for the first time, a C-level executive dedicated to regulatory affairs,At that time, Dr. Susan Alpert served as the Chief Regulatory Officer under the leadership of former CEO Bill Hawkins.

In August 2009, Medtronic appointed Dr. Rick Kuntz as Chief Scientific, Clinical andRegulator, Alpert served asSenior Vice President of Global Regulatory Affairs`, 2011`AlpertRetired from Medtronic. In 2022, Laura Mauri succeeded Kuntz as Chief Scientific, Medical andRegulatorCurrently, Mauri has updated her job title on LinkedIn to Chief Scientific and Medical Officer, and congratulated Pavlovic on his promotion.

In fact, Medtronic has recently announced frequent personnel changes.

On March 29, Gio Di Napoli, President of Medtronic's Gastrointestinal (GI) Business, announced on social media thatOfficially ended a 16-year tenure at MedtronicCareer.In addition, Gio Di Napoli also announced that the new president of the Endoscopy (SE) division has taken office — Raj Thomas, the former vice president and general manager of the company's Mechanical Circulatory Support division.

In February this year, MedtronicBob White, Executive Vice President and President of the Medical Surgical Portfolio, departed due to the merger decision; shortly after, Ariel Mactavish, President of the Respiratory Interventions division, also announced her departure via social media.

And in 2023, MedtronicThe Chinese market has also conductedNew adjustments and layouts, including the significant restructuring of China's cardiovascular platform in March.Medtronic's traditional seven cardiovascular platform teams in the China region will be merged into three, each led by three respective leaders:

• Among them, the Cardiac Rhythm Management, Diagnostics, and Mechanical Circulatory Support businesses, along with Cardiac Ablation Solutions and Cardiac Surgery, have been merged into one team, led by Forrest Lin, former Vice President of Cardiac Rhythm Management, Diagnostics, and Mechanical Circulatory Support.

• The localization of structural heart disease and aortic business in China, as well as the integration of structural heart disease with aortic, peripheral vascular, and venous businesses, will be led by Laura Huang.

• The business of coronary and renal artery sympathetic nerve ablation remains unchanged, continuing to be led by Sam Tao (陶嘉).

Besides,Medtronic has also carried out significant layout optimization and structural adjustments, such as business mergers, factory investments, cost reductions, and growth plans.

Medtronic is a global leading medical technology company dedicated to providing lifelong treatment solutions for patients with chronic diseases, with products coveringCardiovascular diseases, neurological disorders, diabetes, renal diseases, and other fields,Products include various medical devices, equipment, and related healthcare products, such as pacemakers, vascular stents, insulin pumps, etc.

As a medical technology company, Medtronic is also committed to researching and developing new medical technologies. The company has numerous research and development centers and production bases worldwide, with a total workforce of over 90,000 employees.Its business is mainly divided into four major segments: the Cardiovascular Business Group, the Medical Surgical Business Group, the Neuroscience Business Group, and the Diabetes Business Group., covering more than 150 countries and regions worldwide.

Recently, Medtronic announced its third-quarter financial report for the fiscal year 2024, ending on January 26.The report shows that the company's quarterly revenue was $8.1 billion (approximately 58.2 billion RMB), a year-on-year increase of 4.7%.Quarterly net profit was US$1.34 billion, increasing by 8.8% year-on-year.

Screenshot source: Medtronic official website

Medtronic's organic revenue growth reflects the company's overall continued momentum,Mainly benefited from the strong growth of businesses such as diabetes, core spine, cardiac surgery, structural heart, and cardiac pacing, as well as its strength in international markets.

From the perspective of specific business units, all four of Medtronic's businesses achieved positive growth.The growth in the diabetes business was the most significant (12.3%, $640 million).; followed by cardiovascular (6.1%, $2.93 billion); neuroscience (4.3%, $2.36 billion); and medical surgical (3.9%, $2.15 billion).

——

Following a slight decline in financial performance in the fiscal year 2023, Medtronic has also ushered in a "year of transformation."

However, the industry has its ups and downs, and the market has its storms.From a positive perspective, the rotation of Medtronic's personnel can inject new ideas and vitality into the company, help accelerate the pace of business transformation and upgrading, and enhance profitability.

This year, Medtronic also raised its revenue growth and earnings per share (EPS) forecast for the fiscal year 2024, adjusting the organic revenue growth prediction from the previous 4.75% to a new range of 4.75% to 5%.Demonstrates strong confidence in the medical device market.So, next up is MedtronicCan it deliver a perfect answer? Instrumentation Family will continue to follow up.

END

 

More exciting content

Welcome to follow WeChat Video Channel

Instrument Family

Related Reading

Tap for more!

Just now, the chairman of Johnson & Johnson China resigned.

Imaging Unicorn Goes Public Today

First in Asia: Medical Device Giant Invests 1.2 Billion in Shanghai

World's First: Dual Robots Complete Simultaneous Surgeries

Orthopedic Surgical Robots Report Promising Surgery Volumes in Q1, Prelude to Rapid Commercialization May Have Arrived

Just now, the legendary giant plans to lay off 5,000 people

This Innovative Medical Device Embroiled in Bribery Scandal

Largest Third-Party Independent Imaging Company Raises 70 Billion in Refinancing

Just now, the century-old Radiological Society carried out a large-scale layoff.

Fujifilm Invests Another 8.7 Billion

BusinessBusiness cooperation email: qxzj@landianyiliao.com